Compare Stocks: OPK, OMER, and CNTTF

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTTF CannTrust		$0.00	$4.35 ▼ $11.97	$1.01B	4.52	528,025 shs	1.43 million shs
OMER Omeros	$18.27 +2.5%	$18.49	$6.24 ▼ $21.24	$1.32B	2.57	1.63 million shs	886,664 shs
OPK OPKO Health	$1.72	$1.57	$0.98 ▼ $1.81	$1.28B	1.51	3.21 million shs	4.16 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTTF CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
OMER Omeros	-3.31%	+9.45%	-4.19%	+37.79%	+143.25%
OPK OPKO Health	+3.61%	+5.52%	+10.26%	+31.30%	+26.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTTF CannTrust		$0.00	$4.35 ▼ $11.97	$1.01B	4.52	528,025 shs	1.43 million shs
OMER Omeros	$18.27 +2.5%	$18.49	$6.24 ▼ $21.24	$1.32B	2.57	1.63 million shs	886,664 shs
OPK OPKO Health	$1.72	$1.57	$0.98 ▼ $1.81	$1.28B	1.51	3.21 million shs	4.16 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTTF CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
OMER Omeros	-3.31%	+9.45%	-4.19%	+37.79%	+143.25%
OPK OPKO Health	+3.61%	+5.52%	+10.26%	+31.30%	+26.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTTF CannTrust	0.00	N/A	N/A	N/A
OMER Omeros	2.60	Moderate Buy	$30.33	66.03% Upside
OPK OPKO Health	2.71	Moderate Buy	$3.42	98.64% Upside

Current Analyst Ratings Breakdown

Latest OPK, OMER, and CNTTF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	OPK OPKO Health	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$4.00
10/16/2026	OPK OPKO Health	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/16/2026	OPK OPKO Health	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/16/2026	OPK OPKO Health	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$3.00 ➝ $4.00
10/16/2026	OPK OPKO Health	Barrington Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Market Perform ➝ Outperform	$2.25
10/14/2026	OMER Omeros	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$22.00
10/8/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
9/28/2026	OPK OPKO Health	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
9/22/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C) ➝ Hold (C-)
9/22/2026	OMER Omeros	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Overweight	$22.00
9/3/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)

(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTTF CannTrust	$15.96M	0.00	N/A	N/A	N/A	NaN
OMER Omeros	$38.42M	34.42	$1.91 per share	9.55	($1.71) per share	-10.68
OPK OPKO Health	$606.90M	2.12	N/A	N/A	$1.67 per share	1.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTTF CannTrust	N/A	$0.07	137.18	N/A	N/A	N/A	N/A	N/A	N/A
OMER Omeros	-$3.35M	$1.28	14.27	15.10	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)
OPK OPKO Health	-$225.68M	-$0.09	N/A	N/A	N/A	-12.40%	-5.88%	-3.83%	11/4/2026 (Estimated)

Latest OPK, OMER, and CNTTF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	OMER Omeros	$0.02	N/A	N/A	N/A	$37.28 million	N/A
11/4/2026	Q3 2026	OPK OPKO Health	-$0.0680	N/A	N/A	N/A	$136.62 million	N/A
8/12/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTTF CannTrust	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
OPK OPKO Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTTF CannTrust	N/A	N/A	N/A
OMER Omeros	N/A	1.95	1.94
OPK OPKO Health	0.28	3.35	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTTF CannTrust	0.08%
OMER Omeros	48.79%
OPK OPKO Health	64.63%

Insider Ownership

Company	Insider Ownership
CNTTF CannTrust	N/A
OMER Omeros	10.50%
OPK OPKO Health	44.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTTF CannTrust	N/A	105.61 million	N/A	Not Optionable
OMER Omeros	175	72.39 million	64.79 million	Optionable
OPK OPKO Health	1,373	746.33 million	412.57 million	Optionable

OPK, OMER, and CNTTF Headlines

Recent News About These Companies

OPKO Health (NASDAQ:OPK) Sets New 1-Year High - Still a Buy?

November 3 at 10:59 AM | marketbeat.com

OPKO Health (OPK) Set to Post Earnings on Wednesday

November 3 at 3:26 AM | americanbankingnews.com

OPKO Health (OPK) Stock Looks Pricey As Focus Turns To Its 58% Five Year Fall

November 3 at 1:44 AM | finance.yahoo.com

BD Launches Liverty TIPS Stent Graft to Expand U.S. Treatment

November 2 at 3:42 PM | finance.yahoo.com

BrightSpring Q3 Earnings Beat on Specialty Growth, '26 View Raised

November 2 at 3:42 PM | finance.yahoo.com

Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised

October 31 at 1:32 AM | finance.yahoo.com

Reasons to Hold Hinge Health Stock in Your Portfolio for Now

October 31 at 1:32 AM | finance.yahoo.com

DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y

October 31 at 1:32 AM | finance.yahoo.com

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise

October 31 at 1:32 AM | finance.yahoo.com

Analyzing OPKO Health (OPK) & The Competition

October 30, 2026 | americanbankingnews.com

OPKO Health stock unchanged at EUR 1.49 in late quote

October 29, 2026 | ad-hoc-news.deA

OPKO Biologics doses first participant in phase 1/2a trial of OPK-8801001 for treatment of acromegaly

October 28, 2026 | pharmabiz.comP

OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026

October 28, 2026 | finance.yahoo.com

OPKO Health to Report Third Quarter 2026 Financial Results on November 4

October 28, 2026 | quiverquant.comQ

OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026

October 28, 2026 | globenewswire.com

OPKO Health, Inc. (NASDAQ:OPK) Stock Has Average Target Price of $2.96 According to Analysts

October 28, 2026 | americanbankingnews.com

OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly

October 27, 2026 | finance.yahoo.com

OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly

October 27, 2026 | globenewswire.com

Consensus price target for OPKO Health decreases 24.58% to MX$63.94

October 27, 2026 | msn.com

OPKO Health consensus price target decreased by 14.14% to $4.23

October 23, 2026 | msn.com

OPKO Health consensus price target decreased by 14.14% to $4.23

October 23, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OPK, OMER, and CNTTF Company Descriptions

CannTrust OTCMKTS:CNTTF

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Omeros NASDAQ:OMER

$18.27 +0.44 (+2.47%)

Closing price 04:00 PM Eastern

Extended Trading

$18.11 -0.16 (-0.85%)

As of 07:30 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

OPKO Health NASDAQ:OPK

$1.72 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.74 +0.02 (+1.16%)

As of 07:30 PM Eastern

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OPK, OMER, and CNTTF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OPK, OMER, and CNTTF Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OPK, OMER, and CNTTF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OPK, OMER, and CNTTF Company Descriptions

CannTrust OTCMKTS:CNTTF

Omeros NASDAQ:OMER

OPKO Health NASDAQ:OPK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OPK, OMER, and CNTTF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OPK, OMER, and CNTTF Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OPK, OMER, and CNTTF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OPK, OMER, and CNTTF Company Descriptions

CannTrust OTCMKTS:CNTTF

Omeros NASDAQ:OMER

OPKO Health NASDAQ:OPK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools